Nanometer antibody specifically binding to blood coagulation factor VIII and application thereof
By providing nano-antibody specifically binding to coagulation factor VIII, the problem of lack of specific nano-antibody against coagulation factor VIII in the prior art is solved, efficient detection and isolation are achieved, and the cost of treating hemophilia A is reduced. .
Patent Information
- Application Number
- CN202411309855.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-19
- Publication Date
- 2024-11-19
AI Technical Summary
There has been no report of specific nano-antibody against coagulation factor VIII in the prior art, limiting its application in the detection and isolation of coagulation factor VIII.
A nanobody specifically binds to coagulation factor VIII, including specific variable region amino acid sequences, is provided for the preparation and application of coagulation factor VIII for the detection, isolation and treatment of hemophilia A.
A high affinity binding to human coagulation factor VIII is achieved, improving its detection and isolation efficiency and purification effect, reducing costs, and providing a potential drug for the treatment of hemophilia A.
Smart Images

Figure CN118978598A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of nano antibodies, and in particular to a nano antibody specifically binding to coagulation factor VIII and applications thereof. Background Art
[0002] Coagulation factor is an important protein component involved in the coagulation process. Its physiological function is to be activated when the blood vessels bleed, and to adhere to platelets to plug the leaks in the blood vessels. This process is called coagulation. Among hemophilia patients, 80% of patients have hemophilia A (HA), that is, hemophilia A. This type of patients mainly lacks the coagulation factor VIII (FVIII) that normal people have. Hemophilia A is a lifelong disease and there is still no cure. In clinical treatment, directly supplementing the missing coagulation factor VIII is a commonly used treatment method.
[0003] At present, the sources of coagulation factors include plasma separation and recombinant expression. Among them, plasma separation often uses chromatographic separation technology. The difficulty of chromatographic separation technology of plasma proteins lies in the high viscosity of plasma and the huge volume of one-time processing. For the separation of trace plasma proteins such as coagulation factors, affinity chromatography is a more widely used purification method. At present, the industrial purification of recombinant human coagulation factor VIII mainly adopts antibody affinity purification, and its purification effect and efficiency mainly depend on the affinity of the antibody. Therefore, in order to improve the separation and purification effect of human coagulation factor VIII, it is of great significance to explore antibodies that can specifically bind to coagulation factor VIII.
[0004] There is an antibody that naturally lacks light chains in the peripheral blood of alpacas. Its heavy chain is composed of a variable region (VHH) connected to a traditional constant region (CH2-CH3) through a hinge region (Hinge). The variable region VHH alone can specifically bind to the target molecule, and its molecular weight is only about 15KDa, so it is also called a nanobody (Nb). Compared with ordinary antibodies, Nb has the advantages of small molecular weight, strong tissue penetration, high antigen affinity, ability to recognize hidden epitopes, low immunogenicity, stable structure, good water solubility, low production cost, and easy industrialization. It shows great application prospects in the fields of disease diagnosis, disease treatment, small molecule drugs and toxin residue detection. However, there are no reports of specific nanobodies for coagulation factor VIII, which limits the application of antibodies in the detection and separation of coagulation factor VIII. Summary of the invention
[0005] The purpose of the present invention is to overcome the problem in the prior art that there is currently no report on specific nano antibodies against coagulation factor VIII, thereby limiting the use of antibodies in the detection and separation of coagulation factor VIII, and to provide a nano antibody that specifically binds to coagulation factor VIII and its application, wherein the nano antibody can specifically bind to human coagulation factor VIII.
[0006] In order to achieve the above object, the present invention provides, on the one hand, a Nanobody that specifically binds to coagulation factor VIII, wherein the Nanobody comprises a variable region, wherein the variable region comprises a complementary determining region as shown in any one of the following (a) to (g):
[0007] (a) CDR1 with an amino acid sequence as shown in SEQ ID NO: 15, CDR2 with an amino acid sequence as shown in SEQ ID NO: 16, and CDR3 with an amino acid sequence as shown in SEQ ID NO: 17;
[0008] (b) a CDR1 with an amino acid sequence as shown in SEQ ID NO: 18, a CDR2 with an amino acid sequence as shown in SEQ ID NO: 19, and a CDR3 with an amino acid sequence as shown in SEQ ID NO: 20;
[0009] (c) a CDR1 with an amino acid sequence as shown in SEQ ID NO: 21, a CDR2 with an amino acid sequence as shown in SEQ ID NO: 22, and a CDR3 with an amino acid sequence as shown in SEQ ID NO: 23;
[0010] (d) a CDR1 with an amino acid sequence as shown in SEQ ID NO: 24, a CDR2 with an amino acid sequence as shown in SEQ ID NO: 25, and a CDR3 with an amino acid sequence as shown in SEQ ID NO: 26;
[0011] (e) a CDR1 with an amino acid sequence as shown in SEQ ID NO: 27, a CDR2 with an amino acid sequence as shown in SEQ ID NO: 28, and a CDR3 with an amino acid sequence as shown in SEQ ID NO: 29;
[0012] (f) a CDR1 with an amino acid sequence as shown in SEQ ID NO: 30, a CDR2 with an amino acid sequence as shown in SEQ ID NO: 31, and a CDR3 with an amino acid sequence as shown in SEQ ID NO: 32;
[0013] (g) CDR1 with an amino acid sequence as shown in SEQ ID NO: 33, CDR2 with an amino acid sequence as shown in SEQ ID NO: 34, and CDR3 with an amino acid sequence as shown in SEQ ID NO: 35.
[0014] Preferably, the amino acid sequence of the variable region of the Nanobody is as shown in any one of SEQ ID NOs: 1 to 7.
[0015] In a second aspect, the present invention provides a nucleic acid encoding a Nanobody as described above, comprising a nucleic acid sequence encoding the variable region of the Nanobody as shown in any one of SEQ ID NOs: 8 to 14.
[0016] The third aspect of the present invention provides an expression vector, which comprises the nucleic acid as described above.
[0017] A fourth aspect of the present invention provides a host cell, wherein the host cell comprises the expression vector described above.
[0018] Preferably, the host cell is Escherichia coli.
[0019] A fifth aspect of the present invention provides the use of a Nanobody as described above or a nucleic acid as described above in isolating and / or purifying coagulation factor VIII.
[0020] A sixth aspect of the present invention provides the use of the Nanobody as described above or the nucleic acid as described above in detecting coagulation factor VIII.
[0021] A seventh aspect of the present invention provides the use of the nanobody as described above or the nucleic acid as described above in the preparation of a medicament for treating hemophilia A.
[0022] The present invention provides a novel nano-antibody that specifically binds to coagulation factor VIII. These nano-antibodies have a strong affinity for human coagulation factor VIII and can be well applied to the detection and separation of human coagulation factor VIII. In addition, nano-antibodies are easy to produce, and replacing the monoclonal antibodies against coagulation factor VIII currently used in the industry with them can greatly reduce the cost required for the detection and separation of human coagulation factor VIII. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 is the detection result of the diversity of the phage surface library constructed in Example 2 of the present invention;
[0024] Figure 2 is the fragment insertion rate test result of the phage surface library constructed in Example 2 of the present invention;
[0025] Figure 3 This is the affinity test result of the Nanobody in Example 3 of the present invention. DETAILED DESCRIPTION
[0026] The specific embodiments of the present invention are described in detail below. It should be understood that the specific embodiments described herein are only used to illustrate and explain the present invention, and are not used to limit the present invention.
[0027] The endpoints and any values of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoint values of each range, the endpoint values of each range and the individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.
[0028] In this article, "CDR" refers to the complementarity determining region. CDR is also called a hypervariable region and is present in the variable region of a nanobody. In this article, the CDRs of a nanobody are represented by CDR-1, CDR-2, and CDR-3 from the amino terminal side of the amino acid sequence. These sites are close to each other in the tertiary structure and determine the specificity of the antigen to which the antibody binds.
[0029] The present invention provides a nanobody that specifically binds to coagulation factor VIII, the nanobody comprising a variable region, wherein the variable region comprises a complementary determining region as shown in any one of the following (a) to (g):
[0030] (a) CDR1 with an amino acid sequence as shown in SEQ ID NO: 15, CDR2 with an amino acid sequence as shown in SEQ ID NO: 16, and CDR3 with an amino acid sequence as shown in SEQ ID NO: 17;
[0031] (b) a CDR1 with an amino acid sequence as shown in SEQ ID NO: 18, a CDR2 with an amino acid sequence as shown in SEQ ID NO: 19, and a CDR3 with an amino acid sequence as shown in SEQ ID NO: 20;
[0032] (c) a CDR1 with an amino acid sequence as shown in SEQ ID NO: 21, a CDR2 with an amino acid sequence as shown in SEQ ID NO: 22, and a CDR3 with an amino acid sequence as shown in SEQ ID NO: 23;
[0033] (d) a CDR1 with an amino acid sequence as shown in SEQ ID NO: 24, a CDR2 with an amino acid sequence as shown in SEQ ID NO: 25, and a CDR3 with an amino acid sequence as shown in SEQ ID NO: 26;
[0034] (e) a CDR1 with an amino acid sequence as shown in SEQ ID NO: 27, a CDR2 with an amino acid sequence as shown in SEQ ID NO: 28, and a CDR3 with an amino acid sequence as shown in SEQ ID NO: 29;
[0035] (f) a CDR1 with an amino acid sequence as shown in SEQ ID NO: 30, a CDR2 with an amino acid sequence as shown in SEQ ID NO: 31, and a CDR3 with an amino acid sequence as shown in SEQ ID NO: 32;
[0036] (g) CDR1 with an amino acid sequence as shown in SEQ ID NO: 33, CDR2 with an amino acid sequence as shown in SEQ ID NO: 34, and CDR3 with an amino acid sequence as shown in SEQ ID NO: 35.
[0037] In a preferred embodiment, the amino acid sequence of the variable region of the Nanobody is selected from any one of SEQ ID NOs: 1 to 7.
[0038] The nanobody provided by the present invention can specifically bind to coagulation factor VIII of different species, for example, human coagulation factor VIII or cynomolgus monkey coagulation factor VIII. In a specific embodiment, the nanobody can specifically bind to recombinant human coagulation factor VIII.
[0039] The present invention also provides a nucleic acid encoding the Nanobody as described above, which comprises a nucleic acid sequence encoding the variable region of the Nanobody as shown in any one of SEQ ID NOs: 8 to 14.
[0040] The present invention also provides an expression vector, which comprises the nucleic acid described above.
[0041] The present invention also provides a host cell, the host cell comprising the expression vector as described above. When it is necessary to prepare the nanobody, the preparation process includes: culturing the host cell to express the nanobody, and then purifying the expressed nanobody.
[0042] The present invention does not limit the specific type of the host cell, which can be a cell conventionally used for expressing proteins in the art. In a preferred embodiment, the host cell is an Escherichia coli cell.
[0043] The present invention also provides the use of the Nanobody as described above or the nucleic acid as described above in separating and / or purifying coagulation factor VIII.
[0044] In a specific embodiment, the coagulation factor VIII is recombinant human coagulation factor VIII, and the nanobody can specifically bind to the recombinant human coagulation factor VIII with strong affinity. Therefore, when the nanobody or the nucleic acid encoding the nanobody is used to separate and / or purify the recombinant human coagulation factor VIII, the recombinant human coagulation factor VIII can be purified with high purity and high separation efficiency. At the same time, since the preparation of nanobodies is simple, the nanobody described in the present invention can replace the anti-coagulation factor VIII monoclonal antibody currently used for industrial separation and purification, which can greatly reduce the cost of separating and purifying recombinant human coagulation factor VIII.
[0045] In the present invention, the purification is affinity chromatography purification.
[0046] The present invention also proposes the use of the nanobody as described above or the nucleic acid as described above in detecting coagulation factor VIII.
[0047] In a specific embodiment, the coagulation factor VIII is a recombinant human coagulation factor VIII, and the nano antibody can specifically bind to human coagulation factor VIII. The nano antibody provided by the present invention has a strong affinity for recombinant human coagulation factor VIII, so the nano antibody or the nucleic acid encoding the nano antibody can recognize human coagulation factor VIII, and thus can be used to detect human coagulation factor VII; at the same time, due to the convenience of nano antibody production and its particularly small molecular weight, therefore, when the anti-coagulation factor VIII nano antibody of the present invention replaces one or a pair of antibodies in the detection kit, the detection cost is reduced while ensuring the accuracy of the results.
[0048] In the present invention, the detection method is LBA method (ligand binding assay).
[0049] The present invention also proposes the use of the nano-antibody or the nucleic acid as described above in the preparation of a drug for treating hemophilia A.
[0050] The present invention does not limit the specific type and composition of the drug, as long as the nanobody or nucleic acid described above is used in the preparation process. In a specific embodiment, the drug comprises recombinant human coagulation factor VIII, and the nanobody or nucleic acid is used in the separation and purification process of recombinant human coagulation factor VIII.
[0051] The present invention will be described in detail below by way of examples, but the protection scope of the present invention is not limited thereto. The experimental methods in the following examples, unless otherwise specified, are conventional methods in the art. The experimental materials used in the following examples, unless otherwise specified, are commercially available products.
[0052] In the following examples, the antigen used is: recombinant human coagulation factor VIII for injection (rhFVIII, Renjie, Pfizer), which was reconstituted according to the instructions and had a concentration of about 0.3 mg / mL.
[0053] Example 1 Animal Immunization
[0054] 1. Antigen preparation
[0055] 2. Animal selection
[0056] The source of the nanoantibody is alpaca. This operation selects an adult alpaca (Alpaca), 2-3 years old, weighing about 30-40 kg, male, and without immune background.
[0057] 3. Animal immunization method
[0058] 3.1. Specific immunization methods are shown in Table 1 below.
[0059] Table 1
[0060]
[0061] 3.2. Isolation of peripheral blood mononuclear cells (PBMC)
[0062] Inject the lymphocyte separation solution into the density gradient centrifuge tube, injecting 15mL into each tube. At the same time, add an equal volume of phosphate buffered saline (PBS) to the venous peripheral blood to which the anticoagulant has been added to dilute and mix well. Keep the density gradient centrifuge tube vertical and slowly add the diluted venous peripheral blood along the tube wall using a serological pipette. Then use a horizontal rotor centrifuge to centrifuge at room temperature at 1200x g for 10 minutes. After centrifugation, aspirate the top layer of cell-free liquid in the density gradient centrifuge tube and discard it. Be careful to operate slowly and do not disturb the liquid in other layers.
[0063] Slowly aspirate the upper layer containing lymphocytes into a new sterile centrifuge tube, add an equal volume of PBS, and centrifuge at 300 x g for 8 minutes at room temperature to wash the cells. After centrifugation, discard the supernatant and freeze the PBMCs obtained from the bottom precipitate in a -80°C ultra-low temperature refrigerator.
[0064] 3.3. Potency detection
[0065] Take a 96-well ELISA plate and place the antigen, i.e., recombinant human coagulation factor VIII (rhFVIII, ) was diluted with PBS to a 2.5 μg / mL solution, 100 μL / well, and incubated at 4°C overnight.
[0066] The next day, discard the coating solution, use PBST (PBS containing 0.05% v / v Tween-20), 300 μL / well, wash once and discard the liquid, add the prepared blocking solution (4% w / v skim milk prepared in PBS) to the 96-well plate, shake and incubate at room temperature for 2 hours. Then discard the liquid in the well, add 300 μL / well PBST, and wash 3 times.
[0067] Dilute the pre-immune serum and post-immune serum with PBS, starting at 1:200, and perform serial dilutions at a ratio of 1:3 to prepare 8-12 concentration gradients, 50 μL / well, add to a 96-well plate, and incubate at a constant temperature for 1-2 hours. Discard the liquid in the wells, add 300 μL / well PBST, and wash 3 times.
[0068] Dilute Goat pAb anti Llama-IgG HRP according to the instructions, add to 96-well plate, 100 μL / well, incubate at constant temperature for 1 hour. Discard the liquid in the well, add 300 μL / well PBST, and wash 3 times.
[0069] Add TMB colorimetric solution, 100 μL / well, incubate for 10-20 min in dark. Add stop solution, 100 μL / well, mix well. Use an ELISA reader to measure the absorbance at 450 nm.
[0070] The experimental results are shown in Table 2 below.
[0071] Table 2
[0072]
[0073] From the results of serum calibration test in Table 2, it can be seen that when the dilution multiple reaches 1312200, the serum of the alpaca after four immunizations still has obvious antibody binding signals against the antigen (OD value multiple is greater than 2) compared with the serum before immunization, which proves that the immune effect against the antigen is very good. Subsequent monoclonal antibody preparation can be carried out.
[0074] Example 2 Construction and testing of phage surface display library
[0075] 1. Construction of phage surface display library
[0076] The PBMCs separated from all the collected plasma were combined, and total mRNA was extracted using a column adsorption method. The extracted total mRNA was then used as a template for reverse transcription to obtain the corresponding cDNA. Using this cDNA as a template, commercial universal DNA primers for the VHH fragments of alpaca immunoglobulins IgG2 and IgG3 were used to amplify the DNA fragments of the VHH part of alpaca immunoglobulins IgG2 and IgG3 by polymerase chain reaction (PCR), i.e., the DNA fragments of nanobodies.
[0077] The DNA fragment is then treated with restriction endonucleases at both ends, and the phage surface display screening vector DNA plasmid is also treated with the same enzyme digestion. The digested vector is connected to the fragment using T4 DNA ligase to obtain a complete VHH phage surface display screening plasmid library, i.e., a VHH-pIII fusion protein expression vector plasmid library. Among them, pIII is a protein present on the flagella on the surface of the phage. Through this treatment, the exogenous protein is expressed in the form of a fusion protein with pIII. The DNA ligation product is then transformed into Escherichia coli TG1 competent cells by a standard electrotransformation method.
[0078] All collected colonies were cultured according to standard methods to obtain a nanoantibody library against recombinant human coagulation FVIII (hFVIII) derived from alpacas. The library capacity after electroporation was measured by gradient dilution method to be 7.50×10 8 cfu.
[0079] 2. Library diversity detection
[0080] 48 monoclones were randomly selected from the above library, cultured by standard methods, and plasmid DNA was extracted and Sanger sequencing was performed. All sequencing results were translated using corresponding software to obtain amino acid sequences, and mutations such as frameshift and termination were eliminated to count the correct and effective nanobody sequences. The test results are as follows Figure 1 shown.
[0081] Depend on Figure 1 The sequencing results show that 48 monoclonal clones obtained 38 completely different CDR3 nanobody sequences, which means there are 38 different nanobodies. Therefore, from an overall calculation, the CDR3 diversity of the obtained nanobody library is: 7.50×10 8 ×38 / 48=5.94×10 8 cfu.
[0082] 3. Fragment insertion rate test
[0083] Randomly select no less than 48 microbial monoclones from the library and perform PCR amplification on the inserted exogenous fragments, i.e., the VHH fragments of alpaca IgG2 and IgG3. Then, the PCR products are analyzed by agarose gel electrophoresis. The results of agarose gel electrophoresis are as follows: Figure 2 shown.
[0084] Depend on Figure 2 The agarose gel results show that only one of the 48 randomly selected monoclones failed to amplify the exogenous fragment, and the VHH fragment insertion rate was: 47 / 48×100%=97.92%.
[0085] Example 3 Screening of phage surface display library and identification of positive monoclonal nanoantibodies
[0086] The nanobody library obtained above is converted into a phage display antibody library, and the phage display antibody library obtained is screened using a solid-phase antigen to obtain nanobodies that can specifically recognize the antigen.
[0087] Take an appropriate amount of nanoantibody library, inoculate it into bacterial culture medium, add an appropriate amount of helper phage after culturing by standard methods, and continue to culture under appropriate conditions. Use the PEG-NaCl method to extract the amplified phages in the bacterial culture supernatant. These phages carry foreign antibody fragment genes and express the foreign antibody fragments on the phage surface in the form of fusion with PIII protein, which becomes a phage display antibody library.
[0088] An appropriate amount of antigen is made into a solution and added to an immunotube (Maxisorp immunotube, ThermoFisherScientific) so that the antigen is evenly coated on the wall of the immunotube. Then the liquid is discarded, and the phage display antibody library is added to the immunotube so that the phage surface antibody and the antibody are fully contacted and incubated overnight. After appropriate panning and elution steps, the phages that non-specifically bind to the antigen are removed, and the phages that specifically bind to the antigen are collected. The collected phages are infected with Escherichia coli through standard operations to obtain monoclonal nano antibody colonies. After appropriate cultivation, the monoclonal nano antibody colonies can secrete and express the nano antibody in the form of soluble protein. Therefore, the culture supernatant can be verified by ELISA to verify whether the nano antibody can recognize the antigen.
[0089] 1. Monoclonal identification results
[0090] 1.1. The first round of phage display - initial screening
[0091] From the colonies containing nanobodies obtained after the first round of panning, monoclonal colonies were picked up and cultured in 96-well microplates, and IPTG (isopropyl-β-D-thiogalactoside) was added to induce the expression of secretory VHH-pIII fusion protein (fusion protein of pIII of nanobodies). The bacterial culture supernatant containing nanobodies was collected, incubated with the solid-phase antigen, and the non-specifically bound nanobodies were removed after the elution step. Since the VHH-pIII fusion protein expresses His6-tag, the VHH-pIII fusion protein bound to the antigen was detected using a monoclonal antibody to Anti His-tag coupled to horseradish peroxidase (HRP). The positive clones obtained by the detection were saved.
[0092] 1.2. Second round of phage display - initial screening
[0093] The screening steps are the same as described in 1.1.
[0094] 1.3 Phage display-rescreening
[0095] For the positive monoclonal microorganisms obtained in the initial screening, further identification should be repeated to determine whether they can specifically bind to the antigen. The steps are the same as 1.1.
[0096] 1.4. Acquisition and analysis of positive monoclonal DNA sequences and amino acid sequences
[0097] The monoclonal colonies identified as positive after rescreening were picked and cultured overnight at 37°C, and the plasmid DNA was extracted for Sanger sequencing to obtain the DNA sequence of the nanobody and translate it into an amino acid sequence.
[0098] All DNA sequences obtained by sequencing were translated into amino acid sequences, repeated and erroneous sequences were removed, and the correctly translated and single sequences were retained. Among them, the variable region (VHH) gene sequences, amino acid sequences, and amino acid sequence clustering comparisons of the 7 nanobodies described in the present invention are shown in Tables 3-5.
[0099] The amino acid sequences of the variable regions of Nanobodies are shown in Table 3 below.
[0100] Table 3
[0101]
[0102]
[0103] The DNA sequences of the variable regions of the Nanobodies are shown in Table 4 below.
[0104] Table 4
[0105]
[0106]
[0107] The amino acid sequences of the CDRs of the Nanobody variable regions are shown in Table 5 below.
[0108] Table 5
[0109]
[0110]
[0111] 1.5. Recombinant expression and purification of monoclonal nanobodies
[0112] Select the monoclonal plasmid that can secrete nanoantibodies that specifically recognize antigens identified in the above steps, and transform it into BL21 (DE3) E. coli competent cells. In the BL21 (DE3) strain, the nanoantibody is expressed in the bacterial bag as an independent protein (carrying His6-tag), and is not fused with the pIII protein. The monoclonal bacteria obtained after transformation are expanded and cultured, and IPTG is added to induce the nanoantibody to express as an independent protein. After a period of time, the bacteria are collected and broken. After the lysate is centrifuged, the bacterial fragments are removed, and the supernatant is purified by affinity chromatography, and the Co 2+ The binding of the nanobody separates it from other proteins in the bacteria. Excess imidazole is used to competitively bind to the His6-tag 2+ , so that the nanobody carrying the His6-tag is transferred from Co 2+ Elution on the chromatography column. The eluted nanobody solution was concentrated to 0.5 mL. Then, the concentrated nanobody sample was subjected to gel filtration chromatography using a Superdex 75increased chromatography column, and the eluted sample corresponding to a relative molecular mass of 10-20 kDa was collected as the purified nanobody.
[0113] 2. Specificity and affinity testing
[0114] The antigen binding affinity of the nanoantibody obtained in the previous step was tested using the ELISA method. The antigen was coated on a 96-well ELISA plate. After blocking with BSA solution, the diluted purified nanoantibody sample was added. First, the purified nanoantibody was diluted to 10uM, and then a series of gradient dilutions were performed at a ratio of 1:5, resulting in a total of 8 concentration gradients: 0.128nM-10000nM. After incubation, rinsing and other steps, non-specifically bound proteins were removed, and HRP-coupled Anti His-tag HRP monoclonal antibody was added. After adding the HRP substrate, the OD of each well was read using an ELISA instrument. 450 Numeric value.
[0115] The antibody concentration and the OD at the corresponding concentration 450 The values were plotted to obtain the affinity results of each positive clone, wherein the test results of the 7 Nanobodies described in the present invention are as follows Figure 3 and as shown in Table 6.
[0116] Table 6
[0117] Nanobody ID Affinity constant KD (nM) 5B10 183.8 7C7 93.93 5B6 10.57 7F2 161.2 3H5 32.94 3E7 27.47 1E4 59.06
[0118] As can be seen from Table 6, the nanobodies provided by the present invention have good affinity for the antigen (recombinant human coagulation factor VIII). Among them, three nanobodies showed better affinity for the antigen, that is, the KD values were smaller than those of other antibodies, reaching the nM level, namely, nanobodies 3H5, 3E7 and 5B6.
[0119] The preferred embodiments of the present invention are described in detail above, but the present invention is not limited thereto. Within the technical concept of the present invention, the technical solution of the present invention can be subjected to a variety of simple modifications, including the combination of various technical features in any other suitable manner, and these simple modifications and combinations should also be regarded as the contents disclosed by the present invention and belong to the protection scope of the present invention.
Claims
1. A nanobody that specifically binds to coagulation factor VIII, characterized in that The Nanobody comprises a variable region, which comprises a complementarity determining region as shown in any one of the following (a) to (g): (a) CDR1 with an amino acid sequence as shown in SEQ ID NO: 15, CDR2 with an amino acid sequence as shown in SEQ ID NO: 16, and CDR3 with an amino acid sequence as shown in SEQ ID NO: 17; (b) a CDR1 with an amino acid sequence as shown in SEQ ID NO: 18, a CDR2 with an amino acid sequence as shown in SEQ ID NO: 19, and a CDR3 with an amino acid sequence as shown in SEQ ID NO: 20; (c) a CDR1 with an amino acid sequence as shown in SEQ ID NO: 21, a CDR2 with an amino acid sequence as shown in SEQ ID NO: 22, and a CDR3 with an amino acid sequence as shown in SEQ ID NO: 23; (d) a CDR1 with an amino acid sequence as shown in SEQ ID NO: 24, a CDR2 with an amino acid sequence as shown in SEQ ID NO: 25, and a CDR3 with an amino acid sequence as shown in SEQ ID NO: 26; (e) a CDR1 with an amino acid sequence as shown in SEQ ID NO: 27, a CDR2 with an amino acid sequence as shown in SEQ ID NO: 28, and a CDR3 with an amino acid sequence as shown in SEQ ID NO: 29; (f) a CDR1 with an amino acid sequence as shown in SEQ ID NO: 30, a CDR2 with an amino acid sequence as shown in SEQ ID NO: 31, and a CDR3 with an amino acid sequence as shown in SEQ ID NO: 32; (g) CDR1 with an amino acid sequence as shown in SEQ ID NO: 33, CDR2 with an amino acid sequence as shown in SEQ ID NO: 34, and CDR3 with an amino acid sequence as shown in SEQ ID NO:
35.
2. The Nanobody according to claim 1, characterized in that The amino acid sequence of the variable region of the Nanobody is shown in any one of SEQ ID NOs: 1 to 7.
3. A nucleic acid encoding the Nanobody according to claim 1 or 2, characterized in that It comprises a nucleic acid sequence encoding the variable region of the Nanobody as shown in any one of SEQ ID NOs: 8 to 14.
4. An expression vector, characterized in that: The expression vector comprises the nucleic acid of claim 3.
5. A host cell, characterized in that The host cell comprises the expression vector according to claim 4.
6. The host cell according to claim 5, characterized in that The host cell is Escherichia coli.
7. Use of the Nanobody according to claim 1 or 2 or the nucleic acid according to claim 3 in isolating and / or purifying coagulation factor VIII.
8. Use of the Nanobody according to claim 1 or 2 or the nucleic acid according to claim 3 in detecting coagulation factor VIII.
9. Use of the Nanobody according to claim 1 or 2 or the nucleic acid according to claim 3 in the preparation of a medicament for treating hemophilia A.
